Novocellbio Launches Full-Scale Clinical Trials of NK Cell Therapy in Mexico

Monterrey Zambrano Hellion Hospital, Mexico

[Asia Economy Reporter Chunhee Lee] Novocell Bio announced on the 12th that it has completed the NK cell culture experiment of Novocell Bio's NK cell therapy (NOVO-NK) conducted at Monterrey Zambrano Hellion Hospital to obtain final clinical trial approval from Mexico's Texsalud and the Mexican Food and Drug Administration, and will commence full-scale clinical trials.

The two companies previously completed a cell therapy manufacturing facility within Zambrano Hellion Hospital last month. Sara Gonzalez, spokesperson for Texsalud, stated that they will start full-scale clinical trials and patient treatment in both countries in connection with Novocell Bio's biopharmaceutical manufacturing facility in Korea.

First, clinical trials for COVID-19 will begin in the first half of this year, followed by additional clinical trials for breast cancer in the second half. Subsequently, they plan to expand the indications.

This content was produced with the assistance of AI translation services.